European consensus table on the use of botulinum toxin type A in adult spasticity.
A group of clinicians from across Europe experienced in the use of botulinum toxin type A for the treatment of spasticity following acquired brain injury gathered to develop a consensus statement on best practice in managing adults with spasticity. This consensus table summarizes the current published data, which was collated following extensive literature searches, their assessment for level of evidence and discussion among the whole group. Published information is supplemented by expert opinion based on clinical experience from 16 European countries, involving 28 clinicians, who treat an average of approximately 200 patients annually, representing many thousand spasticity treatments with botulinum toxin per year.
Wissel
Jörg
J
Kliniken Beelitz GmbH, Clinical Department of Neurological Rehabilitation, Beelitz-Heilstaetten, Germany. wissel@rehaklinik-beelitz.de
Ward
Anthony B
AB
Erztgaard
Per
P
Bensmail
Djamel
D
Hecht
Martin J
MJ
Lejeune
Thierry M
TM
Schnider
Peter
P
Altavista
Maria C
MC
Cavazza
Stefano
S
Deltombe
Thierry
T
Duarte
Esther
E
Geurts
Alexander C H
AC
Gracies
Jean-Michel
JM
Haboubi
Naseer H J
NH
Juan
Francisco J
FJ
Kasch
Helge
H
Kätterer
Christian
C
Kirazli
Yeşim
Y
Manganotti
Paolo
P
Parman
Yeşim
Y
Paternostro-Sluga
Tatjana
T
Petropoulou
Konstantina
K
Prempeh
Robert
R
Rousseaux
Marc
M
Slawek
Jaroslaw
J
Tieranta
Niko
N
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D020208:Brain Injury, Chronic / Q000150:complications; D032921:Consensus; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications; D007273:Injections, Intramuscular; D009043:Motor Activity / Q000187:drug effects; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000209:etiology; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D020521:Stroke / Q000150:complications
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A